Pharmaceutical Bulk Levofloxacin hydrochloride Powder

CAS:177325-13-2

MF: C18H21ClFN3O4

MW:397.83 

EINECS:605-797-4

Specification: 99% min Levofloxacin hydrochloride Powder

Sample: Levofloxacin hydrochloride Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Levofloxacin hydrochloride Powder Usage and Synthesis.

LevofloxacinHydrochloride is the levofloxacin form of ofloxacin, and its antibacterial activity is about twice as much as that of of ofloxacin, and its main mechanism of action is to inhibit the activity of the bacterial DNA rotamase (bacterial topoisomerase II), and to impede bacterial DNA replication.

Uses and functions of Levofloxacin hydrochloride.

Levofloxacin hydrochloride is indicated for the following mild, moderate and severe infections caused by sensitive bacteria Respiratory system infections: acute bronchitis, chronic bronchitis, acute exacerbation of chronic bronchitis, diffuse fine bronchitis, bronchodilatation co-infections, pneumonia, pharyngolaryngitis, tonsillitis (peri-tonsillar abscess).

Urinary system infections: pyelonephritis, complicated urinary tract infections, etc. Reproductive system infections: prostatitis, epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected).

Skin and soft tissue infections: infectious impetigo, cellulitis, lymphadenitis, subcutaneous abscesses, perianal abscesses.

Intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid fever and paratyphoid fever. Other infections: trauma.

Pharmacological Effects of Levofloxacin hydrochloride.

Its main mechanism of action is to inhibit the activity of bacterial DNA rotamase (bacterial topoisomerase II) and hinder bacterial DNA replication.

It is characterised by wide antimicrobial spectrum and strong antibacterial effect.

It has strong antibacterial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Serratia, Aspergillus, Shigella, Salmonella, Citrobacter, Fusobacterium, as well as gram-negative bacteria such as Pseudomonas aeruginosa, Haemophilus influenzae, and Gonococcus.

It also has good antibacterial effect on some methicillin-sensitive staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus haemolyticus and other Gram-positive bacteria and Legionella, Mycoplasma, Chlamydia, but it has poorer effect on anaerobic bacteria and enterococci.

Production method of Bulk Levofloxacin hydrochloride Powder.

In the synthesis process of levofloxacin hydrochloride in the prior art, levofloxacin is produced by the condensation of levofluorocarboxylic acid and N-methylpiperazine in the presence of a catalyst.

Then the solvent is evaporated and crystallised in a crystallisation solvent and dried to produce a dry product of levofloxacin, and finally levofloxacin hydrochloride is produced by salting levofloxacin with hydrochloric acid and using ethanol to crystallise levofloxacin hydrochloride several times.

The synthesis process in the prior art has the following problems:

(1) Levofloxacin crystals need to be produced first and then salted with hydrochloric acid, which is a long and cumbersome process and not easy to operate;

(2) the use of a catalyst in the production of levofloxacin introduces impurities, resulting in a lower purity of the ultimately produced levofloxacin hydrochloride, which needs to be refined again